



Wishing all our readers a very merry Christmas



Medicine	Traffic light status	Indication	Other Information
Melatonin (Circadin®)	AMBER 2	Parkinson's Disease	RESTRICTED for patients with Parkinson's Disease AND rapid eye movement sleep behavioural disorders (RBD). Unlicensed but in line with NICE CG 71
Eluxadoline (Truberzi® ▼)	AMBER 2	Irritable bowel syndrome with diarrhoea	In line with NICE TA 471 . First 4 weeks to be issued by secondary care with a review ahead of transfer to primary care.

For a full explanation of the Traffic Light definitions, please refer to the [Joint Formulary website](#)

News from the APC

Ratified at the meeting:


(Please note the final documents will be uploaded and available on the APC website within the next 2 weeks to allow for final editing)

- *Lamotrigine prescribing information sheet (Update)*
- *Overactive bladder guidelines (Update)*
- *Dermatology shared care protocols (Update)*
- *Enoxaparin Information sheet (Update)*
- *Position statement on prescribing of homeopathic medicines (Update)*

Procollagen 3 testing

This test is part of the necessary ongoing monitoring which is specified within the dermatology shared care protocol for methotrexate and should be carried out 3 monthly in primary care. This is specific to use of methotrexate in dermatology patients only.

Synonyms	Procollagen, PIIINP, P3NP
Clinical Indications	Monitoring for hepatic fibrosis
Request Form	Combined Pathology Blood form (Yellow/Black)
Patient Preparation	None required.
Specimen	Serum
Volume	2 mL



PIIINP > 7µg/l in at least 3 samples over a 12 month period	Withhold until discussed with dermatology specialist team
PIIINP > 13µg/l in two consecutive samples	Withhold until discussed with dermatology specialist team

Horizon Scanning, Formulary amendments and traffic light changes

Formulary amendments

- Nutritional supplements; cost effective products added to the formulary in line with updated guidance. Dietician advice only. See formulary for full list.
- Famciclovir amended to Amber 2 for genital herpes, as per BASHH guidance
- Mefenamic acid reclassified as Grey, more cost effective options available.
- Sterimar nasal douche added as Grey. Patients should be advised to purchase OTC if required

Horizon scanning

- Inhixa®▼ Biosimilar enoxaparin preparation added as Amber 2
- Enoxaparin; information added to prescribe by brand due to the availability of a biosimilar. Prescribers should ensure that patients are maintained on the same brand where possible, but if a need to switch occurs (e.g. during supply problems) then appropriate patient counselling should take place as there are device differences.

Current work in development

- Trimbow® inhaler - Classified as Grey while a submission is awaited
- Freestyle Libre - Classified as Grey while a submission is awaited
- Ferric Maltol formulary submission
- Prescribing for transgender patients—practice policy
- ADHD shared care for adults
- Emollient Formulary (Review)

Upcoming NICE guidance

TITLE	GUIDELINE/TA	EXPECTED DATE
Asthma management	Guideline	November 2017
Asthma diagnosis and monitoring	Guideline	November 2017
Heavy menstrual bleeding	Guideline	December 2017
Macular degeneration	Guideline	January 2018
Attention deficit hyperactivity disorder	Guideline	February 2018

The work of the NAPC is supported and managed by the interface team below. They can be contacted via MACCG.NoitsAPC@nhs.net if you would like to make a submission or have any queries.

Laura Catt, Prescribing Interface Advisor, NHS Mansfield and Ashfield CCG

Nick Sherwood, Specialist Interface and Formulary Pharmacist, Sherwood Forest Hospitals NHS Foundation Trust

Lynne Kennell, Specialist Interface and Formulary Pharmacist, Sherwood Forest Hospitals NHS Foundation Trust

Irina Varlan, Specialist Interface and Formulary Pharmacist, Nottingham University Hospitals NHS Trust